Pre-eclampsia surgery

Pre-eclampsia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Pre-eclampsia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Pre-eclampsia surgery On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Pre-eclampsia surgery All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Pre-eclampsia surgery
CDC on Pre-eclampsia surgery
Pre-eclampsia surgery in the news
Blogs on Pre-eclampsia surgery
Directions to Hospitals Treating Pre-eclampsia
Risk calculators and risk factors for Pre-eclampsia surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sara Zand, M.D.[2]

Overview

Delivery is the mainstay of therapy for preeclampsia in the 37 weeks of gestation or occurrence of any of the following: repeated episodes of severe hypertension (blood pressure≥ 160/110 mmHg), despite maintenance treatment with 3 classes of antihypertensive agents, progressive thrombocytopenia, progressively abnormal renal or liver enzyme tests, pulmonary edema, abnormal neurological features, stroke, myocardial infarction, HELLP syndrome, eclampsia, suspected acute placental abruption or vaginal bleeding in the absence of placenta previa, abnormal fetal testing, fetal death, fetus without expectation for survival at the time of maternal diagnosis (lethal anomaly, extreme prematurity), or persistent reversed end-diastolic flow in the umbilical artery.

Delivery

Delivery is the mainstay of therapy for preeclampsia in the 37 weeks of gestation or occurrence of any of the following:

• Repeated episodes of severe hypertension (blood pressure≥ 160/110 mmHg, despite maintenance treatment with 3 classes of antihypertensive agents)
• Progressive thrombocytopenia
• Progressively abnormal renal or liver enzyme tests
• Pulmonary edema
• Abnormal neurological features, such as severe intractable headache, repeated visual scotomata, convulsions,Visual disturbances, motor deficit, alteredsensorium
• Stroke
• Myocardial infarction
• HELLP syndrome (hemolysis, elevated liver enzymes, low platelet)
• Eclampsia
• Suspected acute placental abruption or vaginal bleeding in the absence of placenta previa
• Abnormal fetal testing
• Fetal death
• Fetus without expectation for survival at the time of maternal diagnosis (lethal anomaly, extreme prematurity)
• Persistent reversed end-diastolic flow in the umbilical artery